» Articles » PMID: 2339692

Identification of a Frameshift Mutation Responsible for the Silent Phenotype of Human Serum Cholinesterase, Gly 117 (GGT----GGAG)

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 1990 May 1
PMID 2339692
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A frameshift mutation that causes a silent phenotype for human serum cholinesterase was identified in the DNA of seven individuals of two unrelated families. The mutation, identified using the polymerase chain reaction, causes a shift in the reading frame from Gly 117, where GGT (Gly)----GGAG (Gly+ 1 base) to a new stop codon created at position 129. This alteration is upstream of the active site (Ser 198), and, if any protein were made, it would represent only 22% of the mature enzyme found in normal serum. Results of analysis of the enzymatic activities in serum agreed with the genotypes inferred from the nucleotide sequence. Rocket immunoelectrophoresis using alpha-naphthyl acetate to detect enzymatic activity showed an absence of cross-reactive material, as expected. One additional individual with a silent phenotype did not show the same frameshift mutation. This was not unexpected, since there must be considerable molecular heterogeneity involved in causes for the silent cholinesterase phenotype. This is the first report of a molecular mechanism underlying the silent phenotype for serum cholinesterase. The analytical approach used was similar to the one we recently employed to identify the mutation that causes the atypical cholinesterase variant.

Citing Articles

Non-canonical DNA structures: Diversity and disease association.

Bansal A, Kaushik S, Kukreti S Front Genet. 2022; 13:959258.

PMID: 36134025 PMC: 9483843. DOI: 10.3389/fgene.2022.959258.


A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report.

Yu R, Guo Y, Dan Y, Tan W, Mao Q, Deng G BMC Med Genet. 2018; 19(1):58.

PMID: 29631548 PMC: 5891924. DOI: 10.1186/s12881-018-0561-5.


Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).

Zhou G, Marathe G, Hartiala J, Hazen S, Allayee H, Tang W J Biol Chem. 2013; 288(17):11940-8.

PMID: 23508960 PMC: 3636881. DOI: 10.1074/jbc.M112.427674.


Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity.

Panhuizen I, Snoeck M, Levano S, Girard T Case Rep Med. 2010; 2010:472389.

PMID: 20589221 PMC: 2892671. DOI: 10.1155/2010/472389.


Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.

Eng C, Ashley G, Burgert T, Enriquez A, DSouza M, Desnick R Mol Med. 1997; 3(3):174-82.

PMID: 9100224 PMC: 2230047.


References
1.
Prody C, Dreyfus P, Zamir R, Zakut H, Soreq H . De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc Natl Acad Sci U S A. 1989; 86(2):690-4. PMC: 286539. DOI: 10.1073/pnas.86.2.690. View

2.
Hart S, Mitchell J . Suxamethonium in the absence of pseudocholinesterase. Br J Anaesth. 1962; 34:207-9. DOI: 10.1093/bja/34.3.207. View

3.
Endo H, Hasegawa K, Narisawa K, Tada K, Kagawa Y, Ohta S . Defective gene in lactic acidosis: abnormal pyruvate dehydrogenase E1 alpha-subunit caused by a frame shift. Am J Hum Genet. 1989; 44(3):358-64. PMC: 1715432. View

4.
Miura O, Hirosawa S, Kato A, Aoki N . Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest. 1989; 83(5):1598-604. PMC: 303866. DOI: 10.1172/JCI114057. View

5.
Bateman J, Lamande S, Dahl H, Chan D, Mascara T, Cole W . A frameshift mutation results in a truncated nonfunctional carboxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteogenesis imperfecta. J Biol Chem. 1989; 264(19):10960-4. View